An evidence-based staging system for cutaneous melanoma

Area of Science:

• Oncology
• Dermatology
• Cancer Staging

Background:

• The previous staging system for cutaneous melanoma required revision to improve prognostic accuracy.
• A comprehensive analysis of prognostic factors was necessary to update the staging criteria.

Purpose of the Study:

• To validate and finalize the criteria for an evidence-based, revised staging system for cutaneous melanoma.
• To improve the prediction of melanoma outcomes through updated staging criteria.

Main Methods:

• A large-scale prognostic factors analysis involving 17,600 melanoma patients from prospective databases.
• Validation of the revised tumor-node-metastasis (TNM) criteria and stage grouping for all melanoma stages.
• Incorporation of data from lymphatic mapping and sentinel node biopsy for staging conventions.

Main Results:

• Melanoma thickness and ulceration are key predictors for localized disease (Stages I and II).
• Lymph node metastasis number and tumor burden are critical for Stage III melanoma prognosis.
• Distant metastasis site and serum lactate dehydrogenase (LDH) levels predict outcomes in Stage IV melanoma.
• Ulceration of the primary melanoma leads to upstaging across Stages I-III.
• Satellite and in-transit metastases are now classified under Stage III.
• New conventions for clinical and pathological staging account for sentinel node biopsy findings.

Conclusions:

• The revised 2003 staging system provides a more accurate prognostic framework for cutaneous melanoma.
• Key factors like tumor characteristics, lymph node involvement, and distant spread significantly influence melanoma patient outcomes.
• The updated system integrates new diagnostic information, enhancing the precision of melanoma staging.